{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:50:23Z","timestamp":1773888623163,"version":"3.50.1"},"reference-count":121,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2021,11,2]]},"DOI":"10.1080\/14737175.2021.1904895","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T21:24:48Z","timestamp":1615929888000},"page":"1317-1332","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":38,"title":["Ganaxolone treatment for epilepsy patients: from pharmacology to place in therapy"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-0083","authenticated-orcid":false,"given":"Simona","family":"Lattanzi","sequence":"first","affiliation":[{"name":"Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Riva","sequence":"additional","affiliation":[{"name":"Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, \u201cG. Gaslini\u201d Institute, University of Genoa, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6065-1476","authenticated-orcid":false,"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[{"name":"Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, \u201cG. Gaslini\u201d Institute, University of Genoa, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252807.38124.a3"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91208-8"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13025"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16366"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3949"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16546"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2014.05.031"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00759-9"},{"issue":"1","key":"cit0009","first-page":"63","volume":"51","author":"Mensah-Nyagan A","year":"1999","journal-title":"Pharmacol Rev"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.541802"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704543"},{"issue":"3","key":"cit0012","first-page":"333","volume":"40","author":"Wu FS","year":"1991","journal-title":"Mol Pharmacol"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-005-1022-1"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1997.68062412.x"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(01)00071-5"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2013.09.004"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e32833735cf"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1038\/nature05324"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2009.01.006"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.10.1663"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.01059.x"},{"issue":"3","key":"cit0022","first-page":"1284","volume":"280","author":"Carter RB","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.11.003"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1124\/mol.117.108563"},{"issue":"2","key":"cit0025","first-page":"543","volume":"282","author":"Gasior M","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"cit0026","first-page":"868","volume":"284","author":"Beekman M","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440417"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(99)00190-2"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00244.x"},{"issue":"3","key":"cit0030","first-page":"909","volume":"294","author":"Reddy DS","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"cit0031","first-page":"1241","volume":"295","author":"Reddy DS","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(03)02086-7"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.04504.x"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2006.02.011"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.931754"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2009.12.037"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2010.01.009"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2014.08.015"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.12.009"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13999"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.02.020"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.252155"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14693"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2019.11.020"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.261735"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000619"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026179013847"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-183X.2005.00146.x"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4944-04.2005"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.14550"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01486.x"},{"key":"cit0052","first-page":"2365","volume-title":"II. Drugs in more advanced clinical development. Epilepsia","volume":"61","author":"Bialer M","year":"2020"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2015.12.011"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)00447-3"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1386553"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13634"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00324.x"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13705"},{"key":"cit0059","unstructured":"ClinicalTrials.gov. Open-label extension to protocol 1042-0600. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00512317. cited Jan 2021."},{"key":"cit0060","unstructured":"ClinicalTrials.gov. A treatment use protocol for subjects continuing on from the open-label extension 0601. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01002820. cited Jan 2021."},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2015.01.001"},{"key":"cit0062","unstructured":"ClinicalTrials.gov. Phase 3 study of adjunctive ganaxolone in adults with drug-resistant partial onset seizures and open-label extension. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01963208. cited Jan 2021."},{"key":"cit0063","unstructured":"ClinicalTrials.gov. A two-year open-label extension study of ganaxolone in patients with drug-resistant partial-onset seizures. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02519439. cited Jan 2021."},{"key":"cit0064","first-page":"1842","volume-title":"II. Drugs in more advanced clinical development. Epilepsia","volume":"59","author":"Bialer M","year":"2018"},{"issue":"16","key":"cit0065","first-page":"237","volume":"88","author":"Lappalainen J","year":"2017","journal-title":"Neurology"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2013.10.008"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106446"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(18)30244-X"},{"issue":"2","key":"cit0069","first-page":"2","volume":"78","author":"Valdez JM","year":"2018","journal-title":"Medicina (B Aires)"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01182.x"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(00)00170-4"},{"key":"cit0072","unstructured":"ClinicalTrials.gov. A randomized, controlled trial of ganaxolone in patients with infantile spasms. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00441896. cited Jan 2021."},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2014.00063"},{"key":"cit0074","unstructured":"ClinicalTrials.gov. Open-label Extension to Protocol 1042-0500. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00442104. cited Jan 2021."},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2018.02.031"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-008204"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)91731-0"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092091"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.2217\/17455057.3.2.195"},{"issue":"7","key":"cit0080","first-page":"85","volume":"42","author":"McAuley JW","year":"2001","journal-title":"Epilepsia"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00069-1"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)78872-3"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1552616"},{"key":"cit0084","unstructured":"ClinicalTrials.gov. Adjunctive Ganaxolone treatment (Part A) in TSC followed by long-term treatment (Part B). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04285346. cited Jan 2021."},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.02.015"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1002\/dneu.22639"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2015.09.001"},{"key":"cit0088","unstructured":"Pestana-Knight E, Amin S, Cross JH, et al. Ganaxolone significantly reduces major motor seizures associated with CDKL5 deficiency disorder: a randomized, double-blind, placebo-controlled phase 3 study (Marigold study). The American Epilepsy Society Annual Meeting; Virtual; 4-8 December, 2021. Abstract 419. Available at: https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/2422763. cited Jan 2021."},{"key":"cit0089","unstructured":"Pestana-Knight EM, Aimetti A, Hulihan J Effect of ganaxolone on seizure frequency across subpopulations of patients with CDKL5 deficiency disorder: subgroup analyses of the Marigold study. The American Epilepsy Society Annual Meeting; Virtual; 4-8 December, 2021. Abstract 419. Available at: https:\/\/marinuspharma.com\/wp-content\/uploads\/2020\/12\/Ganaxolone_Subgroup_Poster_111820a_FINAL.pdf. cited Jan 2021."},{"key":"cit0090","unstructured":"Hulihan J, Li D, Aimetti A Pharmacokinetic-pharmacodynamic analysis in ganaxolone-treated patients with CDKL5 deficiency disorder: results from the Marigold study. The American Epilepsy Society Annual Meeting; Virtual; 4-8 December, 2021. Available at: https:\/\/marinuspharma.com\/wp-content\/uploads\/2020\/12\/Hulihan_PKPD_Poster_111720b_FINAL.pdf. cited Jan 2021."},{"key":"cit0091","unstructured":"Specchio N, Amin S, Aimetti A, et al. Extended duration safety and efficacy of ganaxolone for the treatment of CDKL5 deficiency disorder: preliminary open-label extension analysis (Marigold study). The American Epilepsy Society Annual Meeting; Virtual; 4-8 December, 2021. Available at: https:\/\/marinuspharma.com\/wp-content\/uploads\/2020\/12\/5_AES2020_Marigold-Prelim-OpenLabel-Analysis.pdf. cited Jan 2021."},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-020-02099-7"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.10.009"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22029"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv245"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13772"},{"key":"cit0097","unstructured":"Sullivan J, Specchio N, Chez MG, et al. Preliminary evidence of a predictive clinical biomarker in PCDH19-related epilepsy: significant treatment effect of ganaxolone in biomarker-positive patients. The American Epilepsy Society Annual Meeting; New Orleans, Louisiana; November 30-December 4, 2018. Abstract 2.251. Available at: https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/502507. cited Jan 2021."},{"key":"cit0098","unstructured":"ClinicalTrials.gov. Study of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy (violet study) Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03865732. cited Jan 2021."},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1810236"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13560"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106466"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.07.004"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00652-0"},{"key":"cit0104","unstructured":"Husain AM, Swisher CB, Ramsay E, et al. Intravenous ganaxolone achieves rapid and dose-dependent sustained improvement in EEG seizure burden in patients with refractory status epilepticus\u201d. The American Clinical Neurophysiology Society Annual Meeting; New Orleans, Louisiana; February 5-9, 2020. Abstract 793677. Available at: https:\/\/marinuspharma.com\/wp-content\/uploads\/2020\/09\/ACN2020-EEG-Seizure-Burden_vFINAL.pdf. cited Jan 2021."},{"key":"cit0105","unstructured":"ClinicalTrials.gov. RAndomized Therapy In Status Epilepticus. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04391569. cited Jan 2021."},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050060"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1017\/S146114570500595X"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12887"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2014.00256"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00166"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4649-y"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2011.01551.x"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2010.01300.x"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.05.007"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2014.04.065"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2020.12.016"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01204-y"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00708-6"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0558-9"},{"key":"cit0120","unstructured":"ClinicalTrials.gov. Ganaxolone Expanded Access Program Compassionate Use (CDD). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04678479. cited Jan 2021."},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.11.022"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2021.1904895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T16:15:11Z","timestamp":1635783311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2021.1904895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":121,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,2]]}},"alternative-id":["10.1080\/14737175.2021.1904895"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2021.1904895","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}